INC Research and inVentiv Health merge in another major CRO deal
Quintiles and IMS Health combined in a megamerger last year, and now INC and inVentiv are doing the same, making it the second largest biopharmaceutical outsourcing provider in the world.
The two CROs will combine in an all-stock transaction and the combined company is set to be worth around $7.4B. INC’s shareholders are expected to own 53% of the combined company, while inVentiv’s will get 47%. Alistair Macdonald, CEO of INC, will become the chief of the merged company, while inVentiv’s CEO, Michael Bell, will become executive chairman. The company will be headquartered in Raleigh, NC where INC is based.
Together, they hope to earn more money through greater offerings to its combined clients, upping its clinical scale and therapeutic depth, all in order to tackle the increasingly complex biopharma environment.
